Introduction to Monoclonal Antibodies in Pain Management

Canine osteoarthritis (OA) is a common degenerative joint disease that causes chronic pain and reduces quality of life. Traditionally, clinicians have relied on nonsteroidal anti-inflammatory drugs (NSAIDs) as the primary treatment. However, the recent introduction of monoclonal antibodies has shifted the therapeutic landscape. The safety of bedinvetmab (Beransa), which targets nerve growth factor (NGF), is now a critical area of study for veterinarians and comparative medicine specialists.

Current Evidence on the Safety of Bedinvetmab

Recent structured literature reviews have analyzed several studies to determine the clinical safety profile of monthly injections. Initially, two short-term studies spanning three months found no significant increase in adverse events (AEs) compared to placebo groups. Furthermore, a comparative trial between bedinvetmab and meloxicam over two months suggested that the monoclonal antibody had fewer associated side effects than the traditional NSAID.

Despite these promising results, a disproportionality analysis revealed a different perspective. This specific study reported that musculoskeletal adverse events occurred significantly more frequently in dogs treated with bedinvetmab than in those receiving other traditional therapies. Consequently, while short-term data is encouraging, clinicians must remain vigilant regarding joint health during extended treatment periods.

Long-Term Safety and Clinical Recommendations

The safety of bedinvetmab remains a topic of conflicting evidence. Stronger data currently supports its use for durations under three months. However, the potential for rapidly progressive osteoarthritis (RPOA)—a phenomenon previously seen in human anti-NGF clinical trials—remains a concern. Future research must incorporate radiographic imaging both before and after treatment to monitor for unusual joint changes or accelerated degradation.

Frequently Asked Questions

Is bedinvetmab safer for the kidneys than NSAIDs?

Because bedinvetmab is a monoclonal antibody metabolized into small peptides and amino acids, it does not rely on the renal or hepatic pathways typically affected by NSAIDs. This makes it a potential alternative for dogs with certain comorbidities, although overall safety monitoring is still required.

What are the most common side effects reported?

The most common adverse events identified in post-marketing surveillance include musculoskeletal issues such as lameness, as well as occasional injection site reactions and skin infections.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical or veterinary advice. Always seek the advice of a qualified professional for the treatment of animals. Refer to the latest local and national guidelines for clinical practice.

References

Yang X et al. A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody. Aust Vet J. 2026 May 05. doi: 10.1111/avj.70088. PMID: 42084864.

Innes JF et al. A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci. 2025;12:1502218.

Kronenberger K. In dogs diagnosed with osteoarthritis, how safe and effective is long-term treatment with bedinvetmab in providing analgesia? Veterinary Evidence. 2023;8(1). doi: 10.18849/ve.v8i1.598.